SLFN11 and neoplasm: Performance status, tumor size, clinical stage and high SLFN11 expression (H-score ≥ 51) were statistically associated with overall survival in univariate analyses (hazard ratio [HR] = 2.98, 95% confidential interval [CI] 1.43–6.19, p = 0.004; HR = 3.76, 95% CI 1.78–7.90, p <  0.001; HR = 5.12, 95% CI 2.45–10.95, p <  0.001; HR = 0.44, 95% CI 0.22–0.87, p = 0.018, respectively).